Severe cutaneous adverse reaction to drug excipient following brand-to-generic switch of levetiracetam
American Journal of Health-System Pharmacy · 2024
DOI: 10.1093/ajhp/zxad264 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Health-System Pharmacy, 2024. Verfasst von Jo Anne Lim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hospital University Sains Malaysia, School of Medical Science, Kota Bharu, Kelantan, and Dermatology Unit, Faculty o…. Hauptthemen laut MEDLINE: Epilepsy, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Purpose
Levetiracetam is an antiepileptic drug known for its high tolerability, and severe adverse drug reactions are rare. We report the case of a severe cutaneous adverse drug reaction in a patient who was switched from brand-name to generic levetiracetam. Summary A 29-year-old woman undergoing contrast-enhanced computed tomography developed lesions over her trunk starting 6 hours after imaging. Although initially diagnosed as an allergy to the radiocontrast agent, the condition progressively worsened into toxic epidermal necrolysis-drug reaction with eosinophilia and systemic symptoms overlap syndrome, despite adequate hydration and treatment. Investigation of the patient’s medications revealed that she had been switched from brand-name to generic levetiracetam a week before the onset of symptoms. Levetiracetam was immediately discontinued, with the patient recovering after 2 weeks of intensive care. Adverse drug reaction analysis identified excipients in generic levetiracetam as the likely cause of the severe reaction.
Conclusion
This is the first reported case of severe cutaneous drug allergy after a brand-to-generic switch for levetiracetam. Brand-to-generic switches of medications can potentially cause severe allergic reactions due to differences in excipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Hospital University Sains Malaysia, School of Medical Science, Kota Bharu, Kelantan, and Dermatology Unit, Faculty of Medicine, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
- Dermatology Unit, Faculty of Medicine, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
- Department of Internal Medicine, Hospital University Sains Malaysia, School of Medical Science, Kota Bharu, Kelantan, Malaysia.
- Reconstructive Sciences Unit, Hospital University Sains Malaysia, School of Medical Science, Kota Bharu, Kelantan, Malaysia.
Zitieren
APA
Lim, J. A., Jamil, A., Ramli, N. A., Johar, F. M., & Nor, M. (2024). Severe cutaneous adverse reaction to drug excipient following brand-to-generic switch of levetiracetam. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxad264
Vancouver
Lim JA, Jamil A, Ramli NA, Johar FM, Nor M. Severe cutaneous adverse reaction to drug excipient following brand-to-generic switch of levetiracetam. American Journal of Health-System Pharmacy. 2024. doi:10.1093/ajhp/zxad264
BibTeX
@article{Lim2024,
author = {Lim, Jo Anne and Jamil, Adawiyah and Ramli, Nur Amalina and Johar, Fatimah Mat and Nor, Mokhtar},
title = {Severe cutaneous adverse reaction to drug excipient following brand-to-generic switch of levetiracetam},
journal = {American Journal of Health-System Pharmacy},
year = {2024},
doi = {10.1093/ajhp/zxad264}
}
EUVIMED